MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation
Status:
Completed
Trial end date:
2020-10-06
Target enrollment:
Participant gender:
Summary
This is a phase I/II study of MLN9708 for the prophylaxis of chronic
graft-versus-host-disease (GVHD) in patients undergoing allogeneic hematopoietic stem cell
transplantation (HSCT).
During the phase I portion, patients undergoing both sibling and unrelated donor
transplantation will be enrolled on the same arm to determine the dose-limiting toxicity
(DLT) and maximum-tolerated dose (MTD).
During the phase II portion of the trial, patients will be enrolled into two separate and
independent cohorts: a) Matched sibling transplants and b) Unrelated donors transplants. Both
cohorts will be enrolled and analyzed separately.